设备治疗在补充当代医疗管理中的作用
Yoel Benarroch1,2, Natalie Tapaskar3, Amin Yehya4,5
1Internal Medicine, Beth Israel Deaconess Medical Center Boston, MA.
US cardiology
|October 20, 2025
概括
新型设备疗法为心力衰竭 (HF) 患者提供了新的希望,补充了传统治疗方法. 本综述探讨了非手术器械的近期进展,其试验结果,以及改善HF护理的机制.
科学领域:
- 心脏病学 心脏病学
- 生物医学工程 生物医学工程
- 临床医学 临床医学
背景情况:
- 心力衰竭 (HF) 是一种复杂的临床综合征,由于心室功能障碍.
- 目前的管理包括生活方式的改变,指导方针导向的医疗治疗,以及解决促成因素.
- 设备疗法的重大进展已经出现,以改善HF发病率和死亡率.
研究的目的:
- 审查心力衰竭的新型非手术设备疗法的当前景观.
- 讨论这些设备的临床试验,主要结果和作用机制.
- 告知临床医生关于新兴疗法,以补充现有的医疗管理.
主要方法:
- 对最近的临床试验和对非手术高频器件的研究进行文献综述.
- 对设备作用机制和目标通路的分析.
- 综合了关于疗效和对HF发病率和死亡率的影响的数据.
主要成果:
- 几种新的非手术装置疗法在改善心力衰竭患者的治疗结果方面表现有前途.
- 这些设备针对涉及高频病理生理学的各种途径.
- 来自试验的证据表明,减少发病率和死亡率具有潜在的益处.
结论:
- 新型非手术器械疗法代表了心力衰竭管理的快速发展和重要的前沿.
- 这些设备可以有效地补充传统的医学疗法.
- 临床医生必须保持对这些进展的了解,以优化患者护理和结果.
相关概念视频
Drug Therapy
239
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
239
Rheumatic Heart Disease III: Medical Management
282
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
282
Diabetes: Management and Pharmacotherapy
861
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
861
Myocarditis III: Medical Management
173
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
173
Therapeutic Drug Monitoring: Affecting Factors
200
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
200
Heart Failure VI: Adjunct Therapies
252
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
252


